【摘要】 为了观察卡培他滨单药治疗蒽环类和紫杉醇类耐药晚期乳腺癌的临床疗效和毒副作用,对以蒽环类及紫杉醇类为基础的化疗方案耐药的晚期乳腺癌25例,应用卡培他滨2 500 mg/(m2.d),口服14 d,21 d为1个周期,观察临床疗效和毒副反应。结果:共化疗112个周期,肿瘤缓解率24%(6/25),临床受益率56%(14/25),中位肿瘤进展时间3.9个月(1~17个月),中位生存期10个月(2.5~>24个月)。Ⅲ、Ⅳ度毒副反应有:Ⅲ度手足综合征3例(12%),Ⅲ度白细胞下降2例(8%),Ⅲ度腹泻1例(4%),Ⅳ度恶心、呕吐1例(4%)。初步研究结果提示,卡培他滨单药化疗蒽环类和紫杉醇类耐药的晚期乳腺癌,疗效确切、毒副反应轻、应用方便。更多还原

【Abstract】 The objective of this study was to investigate the activity and toxicity of single-agent capecitabine in patients with anthracycline-and taxane-pretreated advanced/metastatic breast cancer.Twenty-five patients,which had documented progression after anthracycline-and taxane-containing chemotherapy,were treated with oral capecitabine at a dose of 1 250 mg/m2 twice daily from days 1 to 14 every 21 days.Six patients(24%) obtained a partial response(PR) while 8(32%) had stable disease(SD).This gave a clinical benefit(PR+SD) of 56%.Median time to progression was 3.9 months(1 to 17 months),and median overall survival was 10 months(2.5 to >24 months).Grade Ⅲ hand-foot syndrome was observed in 3 patients(12%).One patient experienced grade Ⅳ nausea and vomiting,while another experienced grade Ⅲ diarrhea.Leucopenia grade Ⅲ was observed in 2 patients(8%).No other grade Ⅲ or Ⅳ toxicity was observed.Oral capecitabine in anthracycline-and taxane-pretreated advanced/metastatic breast cancer appears to be effective and has an acceptable toxicity profile.更多还原